A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies by Gallichotte, E. N. et al.
A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is
the Target of Durable Type-Specific Neutralizing Antibodies
E. N. Gallichotte,a D. G. Widman,b B. L. Yount,b W. M. Wahala,a A. Durbin,c S. Whitehead,d C. A. Sariol,e,f,g J. E. Crowe, Jr.,h
A. M. de Silva,a R. S. Barica,b
Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USAa; Department of Epidemiology, Gillings
School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USAb; Johns Hopkins Bloomberg School of Public Health, Baltimore,
Maryland, USAc; Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USAd; Caribbean
Primate Research Center,e Department of Microbiology and Medical Zoology,f and Department of Internal Medicine,g University of Puerto Rico-Medical Sciences Campus,
San Juan, Puerto Rico, USA; Department of Pediatrics and The Vanderbilt Vaccine Center, Vanderbilt University, Nashville, Tennessee, USAh
ABSTRACT Dengue virus serotype 2 (DENV2) is widespread and responsible for severe epidemics. While primary DENV2 infec-
tions stimulate serotype-specific protective responses, a leading vaccine failed to induce a similar protective response. Using hu-
man monoclonal antibodies (hMAbs) isolated from dengue cases and structure-guided design of a chimeric DENV, here we de-
scribe the major site on the DENV2 envelope (E) protein targeted by neutralizing antibodies. DENV2-specific neutralizing hMAb
2D22 binds to a quaternary structure epitope. We engineered and recovered a recombinant DENV4 that displayed the 2D22
epitope. DENV2 neutralizing antibodies in people exposed to infection or a live vaccine tracked with the 2D22 epitope on the
DENV4/2 chimera. The chimera remained sensitive to DENV4 antibodies, indicating that the major neutralizing epitopes on
DENV2 and -4 are at different sites. The ability to transplant a complex epitope between DENV serotypes demonstrates a hith-
erto underappreciated structural flexibility in flaviviruses, which could be harnessed to develop new vaccines and diagnostics.
IMPORTANCE Dengue virus causes fever and dengue hemorrhagic fever. Dengue serotype 2 (DENV2) is widespread and fre-
quently responsible for severe epidemics. Natural DENV2 infections stimulate serotype-specific neutralizing antibodies, but a
leading DENV vaccine did not induce a similar protective response. While groups have identified epitopes of single monoclonal
antibodies (MAbs), the molecular basis of DENV2 neutralization by polyclonal human immune sera is unknown. Using a recom-
binant DENV displaying serotype 2 epitopes, here we map the main target of DENV2 polyclonal neutralizing antibodies induced
by natural infection and a live DENV2 vaccine candidate. Proper display of the epitope required the assembly of viral envelope
proteins into higher-order structures present on intact virions. Despite the complexity of the epitope, it was possible to trans-
plant the epitope between DENV serotypes. Our findings have immediate implications for evaluating dengue vaccines in the
pipeline as well as designing next-generation vaccines.
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Dengue virus (DENV) is the most significant arboviral infec-tion of humans, with an estimated 390 million infections and
96 million symptomatic cases annually (1). The DENV complex
consists of four distinct serotypes (DENV1 to -4). Infection with
one serotype induces long-term protective immunity to the ho-
mologous serotype only. In fact, immunity to one serotype is as-
sociated with an increased risk of severe disease upon subsequent
infection with a different serotype, a confounding factor for vac-
cine design. Many dengue vaccines in clinical trials are tetravalent
live-attenuated virus formulations that are designed to simultane-
ously induce protective immunity to all 4 serotypes (2–4). How-
ever, in phase 3 efficacy trials in Asia and Latin America, the lead-
ing vaccine was 50 to 78% efficacious against serotypes 1, 3, and 4
but only 35 to 42% efficacious against serotype 2 (5, 6). Moreover,
in vaccinees less than 5 years of age, incidence of hospitalization
for virologically confirmed dengue was ~8-fold higher than that
seen in matched nonvaccinated controls, demonstrating a critical
need for new metrics of protective immunity (7). Here we describe
the main site on DENV2 recognized by type-specific and durable
neutralizing antibodies in people and other primates exposed to
natural infections or a candidate live attenuated DENV2 vaccine.
The DENV envelope (E) glycoprotein is the main target of
protective antibodies (8). The E protein is composed of three do-
mains: I, II and III (designated EDI, EDII, and EDIII, respec-
tively). Each DENV particle has 180 monomers of E that are or-
ganized into 90 dimers that cover the entire surface of the virus
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(9). The arrays of E proteins are arranged with icosahedral sym-
metry, with each asymmetric unit containing three E protein
dimers. Some human monoclonal antibodies (hMAbs) that neu-
tralize DENVs bind to quaternary structure epitopes that require
assembly of E protein into homodimers or higher-order struc-
tures (10–14). Following infection or vaccination, it is a DENV-
specific serum polyclonal antibody response that is responsible for
protection. The principle targets of the human polyclonal anti-
body responses that neutralize DENVs have remained elusive.
We recently described hMAb 2D22, which is a DENV2-specific
strongly neutralizing antibody isolated from a person exposed to a
primary DENV2 infection (10). Our studies also demonstrated
that 2D22 recognizes a complex quaternary epitope displayed on
the intact virus but not recombinant E protein. A point mutation
at amino acid position 323 in EDIII (residue highlighted in ma-
genta in Fig. 1A and B) led to complete escape from 2D22 neutral-
ization, indicating that the epitope includes EDIII residues (10).
Recently Fibriansah et al. solved the structure of 2D22 bound to
DENV2 and demonstrated that the antibody bound to a quater-
nary epitope that was formed by EDIII and EDII on two different
monomers within a single dimer (15). While MAbs are powerful
tools for epitope mapping, it is the polyclonal serum antibody
response derived from long-lived plasma cells that is protective in
people. Here we demonstrate that 2D22 defines a new class of
quaternary epitopes that are the main targets of serum neutraliz-
ing antibodies in people exposed to DENV2 infections or a leading
live attenuated DENV2 vaccine candidate.
RESULTS
Design of rDENV4/2 chimeric virus. To further understand the
role of EDIII in the epitope of 2D22 and DENV2 neutralizing
antibodies in general, we designed and recovered a recombinant
chimeric virus in which the entire DENV2 EDIII region was in-
serted into the backbone sequence of a DENV4 molecular clone to
create a recombinant virus, designated rDENV4/2 (see Fig. S1 and
S2 in the supplemental material). The recombinant virus, which
had 40 amino acid changes in EDIII compared to the parental
wild-type (wt) DENV4 strain (Fig. 1A; see Table S1 in the supple-
mental material), grew to similar levels as the wt viruses in C6/36
insect cells and in a human monocytic cell line (U937) expressing
dendritic cell-specific intercellular adhesion molecule-3-grabbing
nonintegrin (DC-SIGN), a known dengue receptor, but was par-
tially growth impaired in Vero cells (Fig. 1C). DENVs are assem-
bled inside cells as immature virions containing premembrane
proteins (prM), which are cleaved in the Golgi apparatus, result-
ing in the formation of mature virions. Proteolytic cleavage of
prM is inefficient, and the population of virions released from
infected cells is an admixture displaying different stages of matu-
ration. As the maturation state of DENVs may influence the dis-
play of some epitopes and sensitivity to antibody neutralization
(16–18), immunoblots were performed to compare the matura-
tion state of the rDENV4/2 chimera and the wt parental strains.
From C6/36 cells, DENV2 particles had high levels of prM and
DENV4 particles had low levels of prM relative to E protein, indi-
cating that DENV4 virions were more mature (Fig. 1D). The
rDENV4/2 chimera had a maturation state similar to that of
DENV4, indicating that insertion of EDIII from serotype 2 mini-
mally altered the maturation state of the backbone serotype 4 virus
(Fig. 1D).
Monoclonal antibody binding and neutralization of rDENV4/2.
To further evaluate the impact of EDIII exchange on overall E
FIG 1 Design and characterization of rDENV4/2. (A) Amino acid alignment of DENV2 and DENV4 linear envelope domain III (EDIII) sequence, showing
residues 296 to 395 of the entire E sequence (99 amino acids [aa] total). Residues differing between DENV2 and DENV4 are highlighted in yellow. Recombinant
DENV4 virus containing EDIII from DENV2, designated rDENV4/2, replaces differing residues from DENV4 with those from DENV2, highlighted in green
(40 aa total). A residue generated from the escape mutant is highlighted in magenta. (B) Crystal structure model of the DENV2 E protein dimer, with swapped
residues colored in green and the DENV2 type-specific MAb 2D22 escape mutant residue highlighted in magenta. (C) Vero-81 or C6/36 cells were inoculated,
viral supernatants were collected every 24 h, and the viral titer was subsequently determined on the respective cell type, or 1% of U937DC-SIGN cells were
infected, and the total percentage of infection was measured every 12 h (mean  SD). (D) Immunoblotting of C3/36-grown viruses with anti-E and anti-PrM
antibodies. The molecular mass of E is 55 kDa, and the molecular mass of prM is 21 kDa.
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protein topology and virion structure, we probed the rDENV4/2
chimera with a panel of epitope-mapped human and mouse
monoclonal antibodies (see Table S2 in the supplemental mate-
rial). DENV cross-reactive MAbs 1C19, 1N5, and 1M7 bound to
the chimera, indicating the preservation of cross-reactive epitopes
(Fig. 2A) (19). DVC3.7 and DV4-E88 engage serotype-specific
epitopes on EDIII of DENV2 and -4, respectively (Fig. 2B and C;
see Table S2) (20, 21). Consonant with recombinant virus design,
DVC3.7 bound and neutralized the chimera, whereas DV4-E88
failed to bind or neutralize the chimera (Fig. 2F and G). Binding to
and neutralization by 5H2, a nonhuman primate DENV4
serotype-specific MAb with an EDI epitope, is not disrupted in
rDENV4/2, showing we have not affected neutralizing epitopes
present on other domains (Fig. 2D and H; see Table S2) (22).
Overall, these results demonstrate that the rDENV4/2 chimera
displays epitopes in a manner consistent with display on a prop-
erly folded and functional chimeric E protein. Transplantation of
DENV2 EDIII into DENV4 also restored binding and neutraliza-
tion by MAb 2D22, even though this antibody did not bind to
DENV2 recombinant EDIII alone (Fig. 2E and I; see Table S2). We
predict that the full 2D22 epitope required for antibody binding
and neutralization includes EDIII, as well as some conserved res-
idues on adjacent domains, but that the residues on EDIII alone
determine DENV2 specificity. Indeed, the cryo-electron micros-
copy structure of 2D22 bound to DENV2 demonstrates that the
epitope consists of residues on EDIII and EDII of different mono-
mers within a single dimer (15). As the fusion loop region of EDII
is highly conserved across not only DENV but other flaviviruses as
well, we predict it is the variability in EDIII that dictates 2D22
type-specificity. Of the eight contact residues identified in EDIII,
only five differ between DENV2 and DENV4, suggesting these are
critical residues important for 2D22 binding and neutralization
(15).
Polyclonal serum neutralization of rDENV4/2. Natural pri-
mary DENV2 infections cause long-lived serotype-specific neu-
tralizing antibody responses that can be detected for decades after
exposure. To determine if “2D22-like” epitopes created by
DENV2 EDIII transplantation into DENV4 were the main targets
of these antibodies, neutralization assays were performed with
well-characterized human and rhesus macaque dengue immune
sera (see Table S3 in the supplemental material) and the
rDENV4/2 and parental viruses. As expected, primary DENV2
immune sera strongly neutralized DENV2 but not DENV4
(Fig. 3A). Remarkably, in the majority of cases, these sera also
efficiently neutralized the rDENV4/2 virus at levels similar to
those measured with DENV2, indicating that EDIII replacement
FIG 2 Recognition and neutralization of rDENV4/2 virus by DENV-specific monoclonal antibodies. Shown are the results from an ELISA capture assay with
cross-reactive MAbs (A), DENV2-specific EDIII MAb DVC3.7 (B), DENV4-specific EDIII MAb DV4-E88 (C), DENV4-specific EDI MAb 5H2 (D), and
DENV2-specific MAb 2D22 (mean  SD) (E). A Vero-81 cell-based focus reduction neutralization test (FRNT) was performed using DENV2-specific EDIII
MAb DVC3.7 (F), DENV4-specific EDIII MAb DV4-E88 (G), DENV4-specific EDI MAb 5H2 (H), or (I) DENV2-specific MAb 2D22 (I), and FRNT50 values (i.e.,
the concentration of antibody required to neutralize 50% of infection) were calculated (mean  95% confidence interval [CI]). §, FRNT50 of 5 ng/l.
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was sufficient to recreate the major DENV2 neutralizing epitopes
recognized by these sera. The rDENV4/2 virus remained fully sen-
sitive to neutralization by DENV4 immune sera (Fig. 3B). These
data suggest that DENV2 and DENV4 type-specific neutralizing
antibodies target different epitopes on the E protein, which are
both preserved on the rDENV4/2 chimera. To determine if neu-
tralization of rDENV4/2 is specific to DENV2 and DENV4 im-
mune sera and not reflecting a global increase in sensitivity to
neutralization by any dengue immune serum, a panel of primary
DENV1 and DENV3 immune sera were tested against the same
three viruses. The rDENV4/2 virus did not display increased sen-
sitivity to neutralization by DENV1 or DENV3 immune sera (P 
0.05 and P  0.05, respectively), demonstrating that the chimeric
virus was not globally sensitive to antibody neutralization (Fig. 3C
and D).
DENV2 type-specific antibodies require complex epitope. To
determine if the DENV2 neutralizing epitope recognized by anti-
bodies in immune sera was entirely contained within the trans-
planted EDIII or included residues on EDIII and adjacent do-
mains, human immune sera were depleted of antibodies binding
intact DENV2 virions or recombinant DENV2 EDIII (Fig. 4A and
B) and then tested for their ability to neutralize the rDENV4/2
virus (see Fig. S3 in the supplemental material). We have previ-
ously demonstrated that the recombinant DENV2 EDIII protein
is properly folded and contains well-defined epitopes, such as the
lateral ridge and A-strand epitopes recognized by some mouse and
human neutralizing antibodies (23, 24). When six primary
DENV2 human immune sera were depleted using DENV2 virions,
between one-half to three-quarters (68%  21%) of the neutral-
izing potency was lost, depending on the serum sample (Table 1).
When the same sera were depleted using DENV2 rEDIII alone,
five sera displayed minor loss in neutralization (22%  3%), and
one sample (DT110) lost 58% of neutralization, a significantly
smaller loss of neutralization than that of DENV2 depletions (Ta-
ble 1) (P  0.05). These results indicate that most DENV2
epitopes targeted by polyclonal type-specific human neutralizing
antibodies require assembly of more higher-order structures than
simple domains or monomers of E protein. We conclude that
“2D22-like” EDIII-containing quaternary epitopes are a major
target of serotype 2-specific long-lived polyclonal neutralizing an-
tibodies that develop after DENV2 infections.
To determine if dengue vaccines can induce “2D22-like” qua-
ternary epitope-targeted neutralizing antibodies, we tested sera
from 5 subjects who had developed DENV2 neutralizing antibod-
ies after receiving a monovalent live attenuated DENV2 vaccine
developed by the NIH (25). The vaccine sera neutralized DENV2
FIG 3 rDENV4/2 neutralization by human and macaque DENV immune sera. A Vero-81 cell-based focus reduction neutralization test (FRNT) was performed
using primary DENV2 (A), primary DENV4 (B), primary DENV1 (C), primary DENV3 (D), and monovalent DENV2 (E) vaccine immune sera, and FRNT50
values (i.e., the serum dilution factor required to neutralize 50% of infection) were calculated (mean  95% CI). Solid symbols indicate human sera, and open
symbols indicate rhesus macaque sera. Sera that did not block 50% of infection at the lowest serum dilution factor were assigned a value of 10 (1/2 the lower limit
of detection) for graphing and statistical analysis.
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and the rDENV4/2 chimera but not DENV4, demonstrating that
the vaccine induced neutralizing antibodies that tracked with the
transplanted EDIII (Fig. 3E) (P  0.01). To determine if the
vaccine-induced antibodies also recognized a quaternary epitope
that extended beyond EDIII, three vaccine sera were depleted of
antibodies binding intact DENV2 virions or recombinant DENV2
EDIII and then tested for the ability to neutralize the chimeric
virus. In all three samples, depletion with whole virus led to a
nearly complete loss of neutralizing antibodies (Table 1). Removal
of EDIII-specific antibodies resulted in a loss of neutralizing anti-
bodies in one vaccine sample, while the other two samples re-
tained the majority of neutralizing antibodies after EDIII deple-
tion (Table 1). Thus, the vaccine induced neutralizing antibodies
that bind to epitopes contained within EDIII or more complex
epitopes that extend beyond EDIII.
DISCUSSION
We have described an approach using whole-domain replacement
to identify principal antigenic sites targeted by polyclonal anti-
bodies following natural DENV infection or experimental live at-
tenuated DENV vaccination. With the rDENV4/2 chimera, we
observed a clear gain of DENV2 neutralization and no loss of
sensitivity to neutralization by DENV4 sera, suggesting that the
principal DENV4 neutralizing epitopes are distinct from DENV2
epitopes. Importantly, these data demonstrate that a single re-
combinant DENV can be designed that encodes major neutraliz-
ing epitopes from two virus serotypes.
Several recent studies point to the importance of quaternary
epitopes as targets of human DENV neutralizing antibodies (10–
14). DENV1 and 3 neutralizing hMAbs recognize distinct quater-
nary structure epitopes centered at the EDI/II hinge. However,
only a small fraction (3%) of DENV-specific memory B-cell
clones produce strongly neutralizing antibodies (26). It has not
been clear if epitopes defined using human MAbs are the main
targets of the polyclonal serum neutralizing antibody response as
well. Our studies here demonstrate that the DENV2 serotype-
specific epitopes targeted by a human MAb and polyclonal im-
mune sera are closely related if not identical. The epitope is a
complex quaternary epitope and includes critical residues in
EDIII that determine serotype specificity.
The results reveal the fundamental importance of complex
quaternary structures on the surface of DENV particles for driving
potent antibody immune responses. Our results are entirely con-
sistent with the 2D22 epitope structure reported by Fibriansah et
al. in that the antibody footprint contains critical contact residues
on EDIII of one monomer, as well as the fusion loop and BC loop
of EDII on the adjacent monomer, bridging across the dimer (15).
The structure also demonstrates that the 2D22 antibody contact
sites on EDIII are not conserved between serotypes, but the con-
tact sites on EDII are highly conserved between DENV2 and
DENV4 (15). Thus, the serotype specificity of 2D22 is determined
by EDIII, and transplantation of this domain into DENV4 was
sufficient to create the complete functional epitope.
Dengue vaccines have been challenging to develop because of
the need to formulate vaccines with four components that simul-
FIG 4 Depletion of DENV2- and rEDIII-binding antibodies. (A) DENV2 immune sera were depleted using polystyrene beads coated with virus (DENV2
depleted) or BSA (BSA depleted), and removal of DENV2-binding antibodies was confirmed by ELISA, with wells directly coated with DENV2 antigen. (B)
DENV2 immune sera were also depleted using Dynabeads coated with DENV2 rEDIII (rEDIII depleted) or BSA (BSA depleted), and removal of DENV2
rEDIII-binding antibodies was confirmed by ELISA with wells directly coated with rEDIII protein. DT001, IRB019, D031, DT110, DT134, and ss08/90 are sera
from people exposed to natural DENV2 infections. 250.01.02, 250.01.05, and 250.01.19 are sera from people who received the NIH DENV2 vaccine. NHS, normal
human serum.
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taneously induce durable neutralizing and protective antibodies
to each serotype. As the current leading dengue tetravalent vaccine
resulted in increased hospitalization in children under 9 years of
age, there is an urgent need for refined metrics of epitope-specific
neutralization responses. Without knowing the identity of critical
epitopes and regions on viruses of the four serotypes targeted by neu-
tralizing and protective polyclonal serum antibodies, it has been dif-
ficult to dissect tetravalent vaccine responses and efficacy data from
ongoing clinical trials. Epitope-exchanged noroviruses have been
used to decipher complex polyclonal response patterns in vaccine
samples, and it is possible the same techniques can be used with den-
gue tetravalent vaccine sera (27). Our results demonstrate that the
NIH monovalent live attenuated DENV2 vaccine induces neutraliz-
ing antibodies that are similar to those induced by natural infection.
The rDENV4/2 chimera is a powerful tool for evaluating antibody
site-specific responses following infection and vaccine trials. Recom-
binant DENVs expressing quaternary neutralizing antibody epitopes
from 2 or more serotypes may lead to simpler and more effective
vaccines than current tetravalent formulations.
MATERIALS AND METHODS
Virus construction. Recombinant viruses were constructed using a four-
cDNA cloning strategy, the same strategy used to create wt DENV infec-
tious clones (see Fig. S1 in the supplemental material). Patterned after
coronavirus cDNA clones (28, 29), the DENV-4 genome was subcloned
into four separate cDNA plasmids. A T7 promoter was introduced into
the 5= end of the A fragment, and unique type IIS restriction endonuclease
cleavage sites are introduced into the 5= and 3= ends of each fragment to
allow for systematic assembly into a genome-length cDNA from which
full-length transcripts can be derived (28–30).
The EDIII residues from DENV2 were introduced into the DENV4 A
subclone by replacing E nucleotides 900 to 1179 with the corresponding
nucleotides encoding variant DENV2 amino acids. The new A fragment
with nucleotides from DENV2 was synthesized and inserted into the
pUC-57 plasmid (BioBasic). The new A plasmid and the DENV4 B, C, and
D plasmids were grown in Escherichia coli cells, purified, digested with the
corresponding type IIS restriction enzymes, and ligated using T4 DNA
ligase to create a full-length cDNA dengue viral genome. The full-length
cDNA was transcribed into genome-length RNAs using T7 polymerase, as
previously described by our group (28–30). Recombinant RNA was elec-
troporated into BHK-21 cells, and cell culture supernatant containing
viable virus was harvested. Virus was then passaged two times on C6/36
cells, centrifuged to remove cellular debris, and stored at 80°C. Passage
3 represents our working stock.
Cells. Mosquito Aedes albopictus C6/36 cells were grown in Gibco
minimal essential medium (MEM) at 32°C. Vero-81 cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM) and DC-SIGN-
expressing U937 cells (U937DC-SIGN cells) were maintained in RPMI
at 37°C. Medium was supplemented with fetal bovine serum (FBS) (10%
for Vero-81 and 5% for C6/36 and U937DC-SIGN cells), which was
lowered to 2% after infection. The C6/36 and U937DC-SIGN media
were supplemented with nonessential amino acids, and U937DC-SIGN
medium was also supplemented with L-glutamine and 2-mercapto-
ethanol. All media were additionally supplemented with 100 U/ml peni-
cillin and 100 g/ml streptomycin. All cells were incubated in 5% CO2 as
previously described by our group (30).
DENV type-specific PCR and RFLP analysis. Total RNA was isolated
from viral supernatants and used as the template for cDNA synthesis
using standard molecular techniques. Serotype-specific PCR and restric-
tion fragment length polymorphism (RFLP) restriction endonuclease
analyses were performed on cDNA samples in order to validate the purity
of the recombinant viral preparations (see Fig. S2A, B, and C in the sup-
plemental material).
Binding ELISA. Equal quantities of virus (as previously titrated by
enzyme-linked immunosorbent assay [ELISA]) were captured using ei-
ther mouse anti-DENV MAbs 4G2 and 2H2 or human MAb 1C19. Pri-
mary antibodies were diluted 4-fold starting at concentrations ranging
from 10 ng/l to 100 ng/l. Alkaline phosphatase-conjugated secondary
TABLE 1 Neutralization of rDENV4/2 by human immune sera depleted of DENV2- or EDIII-binding antibodiesa
Serum






















DT001 147 82 44 171 131 23
IRB019 931 261 72 372 305 18
DT031 1,288 721 44 1,493 1,140 24
DT110 644 76 88 1,718 729 58
DT134 235 20 91 168 129 23
ss08/90 192 64 67 468 357 24




250.01.02 148 20 100 136 228 0
250.01.05 478 37 92 423 331 22
250.01.19 318 20 100 272 20 100
Avg 97  5 41  53
All sera
Avgb 78  22 32  29
a A Vero-81 cell-based focus reduction neutralization test (FRNT) was performed on sera depleted of DENV2- or rEDIII-binding antibodies, and FRNT50 values (i.e., the serum
dilution factor required to neutralize 50% of infection) were calculated as follows: % loss of neutralization  100  [(DENV2 or rEDIII-depleted FRNT50/BSA-depleted FRNT50)
 100].
b There was a statistically significant difference between the percentage of loss of neutralization of DENV2 depleted and rEDIII depleted by two-tailed t test
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antibodies were used to detect binding of primary antibodies with
p-nitrophenyl phosphate substrate, and reaction color changes were
quantified by spectrophotometry, as previously described (20).
DENV immune sera. Deidentified human DENV immune sera were
collected from individuals with confirmed previous natural DENV
infections (see Table S2 in the supplemental material). All donations
were collected in compliance with the Institutional Review Board of
the University of North Carolina at Chapel Hill (protocol 08-0895).
Deidentified human immune sera previously collected from adults
given the NIH monovalent DENV2 vaccine (ClinicalTrials.gov identifier
NCT00920517) was provided by Anna Durbin and Stephen Whitehead.
All sera were collected following informed consent and approval by the
Western Institutional Review Board. Nonhuman primate immune sera
were collected following experimental DENV infection and kindly pro-
vided by Carlos Sariol (see Table S2) (31). All procedures were reviewed
and approved by the Institute’s Animal Care and Use Committee at Med-
ical Sciences Campus, University of Puerto Rico (IACUC-UPR-MSC) and
performed in a facility accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC) (Animal Welfare
Assurance no. A3421; protocol no. 7890108, 7890208, 7890209, and
7890210).
Virus titration and FRNT. One day prior to inoculation, 24-well cell
culture plates were seeded with either 5  104 Vero-81 cells or 1  105
C6/36 cells. Prior to inoculation, growth medium was removed. Virus
titrations were performed by serially diluting virus stocks 10-fold and then
incubating them for 1 h at 37°C. After incubation, virus dilutions were
added to cells for 1 h at 37°C and then overlaid with 1 ml 1% methylcel-
lulose in OptiMEM I (Gibco) supplemented with 2% FBS, 100 U/ml pen-
icillin, and 100 g/ml streptomycin. After 3 to 6 days of incubation at
37°C, the overlay was removed, and cells were washed with phosphate-
buffered saline (PBS) and fixed in 80% methanol. Plates were blocked
with 5% instant milk made in PBS and then incubated with anti-E MAb
4G2 and anti-prM MAb 2H2, both diluted 1:500 in blocking buffer. The
plates then were washed and incubated with horseradish peroxidase
(HRP)-conjugated goat anti-mouse antibody (Sigma), diluted 1:2,500 in
blocking buffer. Plates were washed, foci were developed with TrueBlue
HRP substrate (KPL), and then foci were counted.
For the focus reduction neutralization test (FRNT), either MAbs or
sera were diluted 4-fold and mixed with ~40 focus-forming units (FFU) of
virus and then incubated for 1 h at 37°C. After incubation, virus and MAb
or serum dilutions were added to cells for 1 h at 37°C, and then the overlay
was added and processed as described above.
Growth curves. Either Vero or C6/36 cells were inoculated at a mul-
tiplicity of infection (MOI) of 0.01. Every 24 h, culture supernatant was
harvested and centrifuged to remove cellular debris. Samples were frozen
at 80°C until use. Fresh medium was replaced each day. Virus titers were
determined on their propagating cell type, as described above.
U937DC-SIGN cells were infected at an initial infection of 1%, and
every 12 h, a sample of cells was harvested, fixed, permeabilized, and
probed with 2H2 (anti-prM antibody) conjugated to Alexa Fluor 488.
Infected cells were quantified using a Guava flow cytometer (Millipore).
Immunoblotting. Virus stocks were diluted in PBS, mixed with 4
Laemmli sample buffer (Bio-Rad), and heated for 10 min at 50°C. Samples
were run on 12% Protean TGX gels (Bio-Rad), transferred to polyvi-
nylidene difluoride (PVDF) membrane, and blocked in 5% instant milk in
PBS plus 0.05% Tween overnight at 4°C. Membranes were probed with
0.5 g/ml anti-E MAb 4G2, 0.5 g/ml anti-prM MAb 2H12, and MAb
5L20 in blocking buffer for 2 h at 37°C. After washing, HRP-conjugated
anti-mouse or anti-human secondary antibodies were diluted 1:10,000 in
blocking buffer and incubated for 1 h at room temperature. Membrane
was exposed to chemiluminescent substrate and developed on film.
Depletion of DENV2-specific antibodies from immune sera. Poly-
clonal immune sera were depleted of DENV2-binding antibodies as pre-
viously described (10). Briefly, polystyrene microspheres (Polysciences
catalog no. 17135) were coated with purified DENV2 antigen (Microbix
catalog no. EL-22-02-001) or the bovine serum albumin (BSA) control.
Immune sera were depleted of antibodies by incubation with coated beads
for 45 min at 37°C for at least three rounds, until maximum depletion of
antibodies was measured. Depletions of antibodies were confirmed by
ELISA.
Depletion of rEDIII-specific antibodies from immune sera. Poly-
clonal immune sera were depleted of rEDIII-binding antibodies as previ-
ously described for rE-binding antibodies (10). Briefly, Dynabeads (Life
Technologies catalog no. 14302D) were covalently conjugated to DENV2
rEDIII protein following the manufacturer’s protocol or BSA control.
Immune sera were depleted of antibodies by incubation with conjugated
beads for 45 min at 37°C for at least three rounds, until maximum deple-
tion of antibodies was measured. Depletions of antibodies were confirmed
by ELISA.
ELISA confirmation of DENV2 or rEDIII-depleted sera. ELISA
plates were coated directly with either 50 ng of DENV2 antigen or 100 ng
DENV2 rEDIII per well at 4°C overnight. Plates were blocked as described
above. Undepleted, control depleted, and antigen/rEDIII-depleted sera
were diluted 1:40 in blocking buffer and were incubated on plates for 1 h
at 37°C. DENV2 or rEDIII reactive antibodies were detected using the
secondary antibody and substrate as described above.
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